Table 3. Treatment of COVID-19 patients.
| Total (n=238) | Clinical classification | *P value | ||
| Mild / General (n=190) | Severe / Critical (n=48) | |||
| Complications, No. (%) | 15 (6.3) | 3 (1.6) | 12 (25.0) | <.001 |
| Antiviral therapy, No. (%) | ||||
| Lopinavir/Ritonavir alone | 70 (29.3) | 64 (33.7) | 6 (12.5) | 0.004 |
| Lopinavir/Ritonavir + Interferon (analogues) | 97 (40.8) | 92 (48.4) | 5 (10.4) | <.001 |
| Interferon (analogues) | 35 (14.7) | 32 (16.8) | 3 (6.25) | 0.06 |
| Arbidol alone | 16 (6.7) | 11 (5.8) | 5 (10.4) | 0.33 |
| Arbidol + Interferon (analogues) | 11 (4.6) | 11 (5.8) | 0 (0) | 0.13 |
| Xuebijing (TCM) | 17 (7.1) | 10 (5.3) | 7 (14.6) | 0.03 |
| Chloroquine phosphate | 3 (1.3) | 3 (1.6) | 0 (0) | >.99 |
| Immunosuppressive therapy, No. (%) | ||||
| Glucocorticoid therapy | 76 (31.9) | 28 (14.7) | 48 (100) | <.001 |
| Gamma-globulin therapy | 75 (31.5) | 27 (14.2) | 48 (100) | <.001 |
| Respiratory support, No. (%) | ||||
| Oxygen inhalation | 48 (20.2) | 0 (0) | 48 (100) | <.001 |
| Mechanic ventilation | 4 (1.7) | 0 (0) | 4 (8.3) | 0.002 |
| ECMO | 1 (0.4) | 0 (0) | 1 (2.1) | 0.20 |
Abbreviations: TCM, traditional Chinese medicine; ECMO, extracorporeal membrane lung oxygenation.
* P values indicate differences between mild / general type and severe / critical patients. P < .05 was considered statistically significant.